New study uses xenon MRI to see how a triple inhaler helps COPD lungs
NCT ID NCT07192016
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 29 times
Summary
This study looks at how a once-daily triple inhaler (fluticasone furoate, umeclidinium, and vilanterol) affects lung function in adults with moderate-to-severe COPD. Researchers will use a special type of MRI (129-Xenon) to see how well air moves through the lungs. The study includes 60 participants aged 50-85 who will take the inhaler daily for 12 weeks (with an optional extension to 48 weeks) and undergo lung tests and imaging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.